The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon α-2b and ribavirin for chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 9, 2007, Pages 733-739

  Nakamura, Junichiro ^a,b   Kobayashi, Kuriko ^a   Toyabe, Shin Ichi ^a   Aoyagi, Yutaka ^a   Akazawa, Kouhei ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Cost effectiveness; Peginterferon 2b; Rapid virologic response; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; JAPAN; MARKOV CHAINS; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34547932217     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282748f1f     Document Type: Article

References (42)

1. World Health Organization (WHO). Available at: http://www.who.int/ vaccine_research/disease/viral_cancers/en/index2/htm. Accessed 13 January 2007.
2. National Institutes of Health. Consensus Development Conference Statement: Management of Hepatitis C, June 2002. Available at: http://www.consensus.nih.gov Accessed 2 March 2007.
3. El-Serag HB, Devila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139:817-824.
4. Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000; 36:909-915.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965.
6. Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99:1298-1305.
7. Strader DB, Wright T, Thomas DL, Seeff LB. The American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
8. Sullivan SD, Craxi A, Alberti A, Guiliani G, Decarli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22:257-265.
9. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17:687-694.
10. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432.
11. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98:2354-2362.
12. Buti M, Casado MA, Fosbrook L, Esteban R. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha- 2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 2005; 23:1043-1055.
13. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
14. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Eng J Med 2005; 352:2609-2617.
15. Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, Mcquillan G, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131:478-484.
16. Beck JR, Pauker SG. The medical process in medical prognosis. Med Decis Making 1983; 3:419-458.
17. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-338.
18. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88:240-243.
19. Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 1993; 27:812-816.
20. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotype 1 and 2 hepatitis C virus. Hepatology 1996; 23:695-699.
21. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998; 351:1773-1777.
22. Kaneko S, Unoura M, Takeuchi M, Terasaki S, Ogino H, Matsushita E, Kobayashi K. The role of hepatitis C virus in hepatocellular carcinoma in Japan. Intervirology 1994; 37:108-113.
23. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
24. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-1440.
25. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994; 74:2234-2238.
26. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
27. Ikeda K, Saitoh S, Koida I, Arase Y, Tsumota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18:47-53.
28. Tanaka K, Sakai H, Hashizume M, Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 1998; 89:1241-1250.
29. Miyakawa H, Izumi N, Marumo F, Sato C. Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 1996; 20:91A-94A.
30. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55:1332-1338.
31. OECD. Main economic indicators. Paris, France: OECD; 2006.
32. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43:1303-1310.
33. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53:744-749.
34. Abridged life table for Japan. 2004. Tokyo: Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour, and Welfare, 2005.
35. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253-1258.
36. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334-1340.
37. Short course pegintron plus rebetol approved in Europe for HCV patients with genotype 1 and low viral load. Available at: http://www.hivandhepatitis. com/hep_c/news/2005/ad/100705_a.html. Accessed 13 January 2007.
38. Wong JB, Zeuzem S, Manns MP, Albrecht JK. Clinical and economic implications of a 4-week viral negative response to peginterferon alfa-2b plus ribavirin for chronic hepatitis C and genotype 1 with low viral load. Hepatology 2005; 42:679A.
39. Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-1265.
40. Wagner MV, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-a-za (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
41. Davis GL, Wong JB, McHutchson JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
42. Berg T, Wagner MV, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.